Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Transfusion ; 45(6): 911-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15934989

ABSTRACT

BACKGROUND: Several strategies are being developed to reduce the risk of pathogen transmission associated with platelet (PLT) transfusion. STUDY DESIGN AND METHODS: The impact of a new technology for pathogen reduction based on riboflavin plus illumination (Mirasol PRT, Navigant Biotechnologies, Inc.) at 6.2 and 12.3 J per mL on functional and biochemical characteristics of PLTs was evaluated. PLT concentrates (PCs) obtained by apheresis were treated with Mirasol PRT and stored at 22 degrees C. Modifications in major PLT glycoproteins (GPIbalpha, GPIV, and GPIIb-IIIa), adhesive ligands (von Willebrand factor [VWF], fibrinogen [Fg], and fibronectin), activation antigens (P-selectin and LIMP), and apoptotic markers (annexin V binding and factor [F]Va) were analyzed by flow cytometry. Adhesive and cohesive PLT functions were evaluated with well-established perfusion models. Studies were performed on the preparation day (Day 0) and during PCs storage (Days 3 and 5). RESULTS: Levels of glycoproteins remained stable during storage in PCs treated with 6.2 J per mL pathogen reduction technology (PRT) and similar to those observed in nontreated PCs. When 12.3 J per mL PRT was applied, however, levels of GPIbalpha moderately decreased on Days 3 and 5. VWF, Fg, and FVa were not modified in their expression levels, either by treatment or by storage period. Fibronectin appeared more elevated in all PRT samples. A progressive increase in P-selectin and LIMP expression and in annexin V binding was observed during storage of PRT-treated PCs. Functional studies indicated that 6.2 J per mL Mirasol PRT-treated PLTs preserved adhesive and cohesive functions to levels compatible with those observed in the respective control PCs. CONCLUSION: PLT function was well preserved in PCs treated with 6.2 J per mL Mirasol PRT and stored for 5 days.


Subject(s)
Blood Platelets , Blood Platelets/drug effects , Blood Platelets/radiation effects , Blood Preservation , Riboflavin/pharmacology , Ultraviolet Rays , Annexin A5/analysis , Annexin A5/drug effects , Annexin A5/radiation effects , Antigens, CD/analysis , Antigens, CD/drug effects , Antigens, CD/radiation effects , Blood Platelets/chemistry , Blood Platelets/cytology , Blood Platelets/physiology , Fibrinogen/analysis , Fibrinogen/drug effects , Fibrinogen/radiation effects , Fibronectins/analysis , Fibronectins/drug effects , Fibronectins/radiation effects , Flow Cytometry , Humans , Lysosomal Membrane Proteins , P-Selectin/analysis , P-Selectin/drug effects , P-Selectin/radiation effects , Platelet Activation/drug effects , Platelet Activation/radiation effects , Platelet Adhesiveness/drug effects , Platelet Adhesiveness/radiation effects , Platelet Count , Platelet Glycoprotein GPIIb-IIIa Complex/analysis , Platelet Glycoprotein GPIIb-IIIa Complex/drug effects , Platelet Glycoprotein GPIIb-IIIa Complex/radiation effects , Platelet Glycoprotein GPIb-IX Complex/analysis , Platelet Glycoprotein GPIb-IX Complex/drug effects , Platelet Glycoprotein GPIb-IX Complex/radiation effects , Platelet Membrane Glycoprotein IIb/analysis , Platelet Membrane Glycoprotein IIb/drug effects , Platelet Membrane Glycoprotein IIb/radiation effects , Platelet Transfusion , Plateletpheresis , Temperature , Time Factors , von Willebrand Factor/analysis , von Willebrand Factor/drug effects , von Willebrand Factor/radiation effects
2.
J Thromb Haemost ; 1(11): 2411-8, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14629477

ABSTRACT

BACKGROUND: Pigs have been widely used as animal models to study hemostasis. However, there are significant differences when comparing the hemostatic behavior of pig and human platelets. OBJECTIVE: To investigate signaling through tyrosine-phosphorylation of proteins in pig platelets after activation in suspension or by adhesion under flow conditions, in comparison with human platelets. METHODS: Activation of platelet suspensions was performed with thrombin (T; 0.1 and 1 U mL(-1)) and type I collagen (Col-I; 20 microg mL(-1)), at two different time points (30 and 90 s). Activation by adhesion was carried out on Col-I-coated coverslips, using citrated whole blood samples perfused through a parallel-plate chamber. RESULTS AND CONCLUSIONS: Significant differences between pig and human platelets were detected before and after activation. Activation of pig platelets required higher concentrations of thrombin, as well as increased activation times, to achieve similar levels of tyrosine phosphorylation. Proteins p160, p140, p85 and pp62, present in human platelets, were not detected in profiles corresponding to activated pig platelets. A protein of 70 kDa appeared only in pig platelet profiles, p55 was highly phosphorylated, and the phosphorylation levels of some proteins were significantly different from those found in human platelet profiles. In profiles corresponding to adhered pig platelets, p85 and p62 were absent, and p115 appeared highly phosphorylated. As observed in suspension studies, p70 and p55 appeared specifically in adhered pig platelets. Our study shows that the phosphotyrosine proteins involved in the activation of pig platelets are significantly different from those observed in activated human platelets. These findings may help to explain the differing adhesive and cohesive properties of platelets from both species, which should be considered when extrapolating results.


Subject(s)
Blood Platelets/metabolism , Phosphoproteins/metabolism , Swine/blood , Tyrosine/metabolism , Animals , Blood Platelets/chemistry , Humans , Kinetics , Phosphorylation , Platelet Activation , Signal Transduction , Thrombin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...